Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001213900-26-039352
- form_type
- 8-K
- ticker
- SILO
- cik
- 0001514183
- company_name
- Silo Pharma, Inc.
- filed_at
- 2026-04-02T23:59:59+00:00
- discovered_at
- 2026-05-14T18:02:32.397275+00:00
- generated_at
- 2026-05-15T07:50:01.148858+00:00
- sec_items
- ["1.01", "3.02", "9.01"]
- event_type
- m_and_a
- sentiment
- neutral
- materiality_score
- 0.4
- calibrated_materiality_score
- 0.4
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001213900-26-039352
- json_url
- https://secwatch.observer/filing/0001213900-26-039352.json
- markdown_url
- https://secwatch.observer/filing/0001213900-26-039352.md
- text_url
- https://secwatch.observer/filing/0001213900-26-039352.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1514183/000121390026039352/0001213900-26-039352-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1514183/000121390026039352/ea0284319-8k_silo.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
LOKV
Live Oak enters forward purchase agreement to reduce redemptions for Teamshares merger
Live Oak Acquisition Corp. V
June 2, 2026, 9:09 AM ET
m_and_a
Items 1.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 9.01
same event type: m_and_a
similar materiality
This filing
On July 29, 2025, Silo Pharma, Inc. (the “Company”) entered into an asset purchase agreement (the “Agreement”) with Many Ads Inc. (the “Seller”).
Comparable filing
On June 1, 2026, Live Oak Acquisition Corp. V, a Cayman Island exempted company (“ Live Oak ”), and a fund sub-advised by JBA Asset Management LLC (“ Seller ” or “ FPA Investor ”) entered into an agreement (the “ Forward Purchase Agreement ”) for an OTC Prepaid Share Forward Transaction-Optional Early Termination
Filing page
SEC filing
KLXE
KLX Energy acquires Wolfpack assets for $17M; also exchanges $2.19M notes for equity
KLX Energy Services Holdings, Inc.
June 2, 2026, 5:14 PM ET
m_and_a
Items 1.01, 2.01, 3.02, 7.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 3.02, 9.01
same event type: m_and_a
This filing
On July 29, 2025, Silo Pharma, Inc. (the “Company”) entered into an asset purchase agreement (the “Agreement”) with Many Ads Inc. (the “Seller”).
Comparable filing
Purchase and Sale Agreement On June 2, 2026 (the “Closing Date”), KLX Energy Services Holdings, Inc., a Delaware corporation (the “Company”), completed the acquisition (the “Acquisition”) of certain assets owned by Wolf Pack Rentals, LLC, a Texas limited liability company (“Wolf Pack” or the “Seller”), pursuant to that certain asset purchase agreement, dated June 2, 2026 , by and among Wolf Pack, KLX Energy Services LLC, a Delaware limited liability company and indirect wholly owned subsidiary of the Company (the “Buyer”), the Company and, solely for purposes of Section 8.05 thereto, Stevie Cooper and Stewart Cooper (the “Purchase Agreement”).
Filing page
SEC filing
XRN
Chiron Real Estate closes $249M acquisition of two senior housing communities; issues $100M Series C preferred
Chiron Real Estate Inc.
June 2, 2026, 4:30 PM ET
m_and_a
Items 1.01, 2.01, 2.03, 3.02, 3.03, 5.03, 9.01
same fact type: material_agreement
same SEC item: 1.01, 3.02, 9.01
same event type: m_and_a
This filing
On July 29, 2025, Silo Pharma, Inc. (the “Company”) entered into an asset purchase agreement (the “Agreement”) with Many Ads Inc. (the “Seller”).
Comparable filing
Item 1.01 Entry into a Material Definitive Agreement Seventh Amendment to the Agreement of Limited Partnership of Chiron Real Estate LP On May 28, 2026, Chiron Real Estate Inc. (the “ Company ”), as the sole member of the general partner of Chiron Real Estate LP (the “ Operating Partnership ”), entered into an amendment to the agreement of limited partnership of the Operating Partnership (the “ OP Amendment ”).
Filing page
SEC filing
SCOR
comScore sells Movies Business for $70M cash to Advaya Capital affiliate; repays $40.1M debt
COMSCORE, INC.
June 2, 2026, 5:12 PM ET
m_and_a
Items 1.01, 1.02, 2.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 9.01
same event type: m_and_a
This filing
On July 29, 2025, Silo Pharma, Inc. (the “Company”) entered into an asset purchase agreement (the “Agreement”) with Many Ads Inc. (the “Seller”).
Comparable filing
On May 27, 2026, comScore, Inc. (the "Company"), entered into an Equity Purchase Agreement (the "Purchase Agreement") with an affiliate of Advaya Capital, Flix Buyer Inc. (the "Purchaser"), pursuant to which the Company sold its box office measurement, reporting and analytics business and its Hollywood Software business (collectively, the "Movies Business"), including 100% of the interests of Rentrak, LLC ("Rentrak"), an Oregon limited liability company and wholly owned subsidiary of the Company, to the Purchaser for an aggregate base purchase price of $70.0 million in cash, subject to customary adjustments and other terms as more fully set forth in the Purchase Agreement (the "Transaction").
Filing page
SEC filing
ISRLF
Israel Acquisitions Corp extends Gadfin deal deadline to June 15, 2026
Israel Acquisitions Corp
June 2, 2026, 4:15 PM ET
m_and_a
Items 1.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 9.01
same event type: m_and_a
This filing
On July 29, 2025, Silo Pharma, Inc. (the “Company”) entered into an asset purchase agreement (the “Agreement”) with Many Ads Inc. (the “Seller”).
Comparable filing
On May 31, 2026, the Company, Gadfin, and Gadfin Regev Holdings Ltd., a company domiciled in Israel, entered into a sixth amendment to the BCA (the “ Sixth BCA Amendment ”).
Filing page
SEC filing
HVII
HVII extends business combination with ONE Nuclear to August 15, 2026; increases promissory note to $317K
Hennessy Capital Investment Corp. VII
June 2, 2026, 4:15 PM ET
m_and_a
Items 1.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 9.01
same event type: m_and_a
This filing
On July 29, 2025, Silo Pharma, Inc. (the “Company”) entered into an asset purchase agreement (the “Agreement”) with Many Ads Inc. (the “Seller”).
Comparable filing
(ii) the maturity date of the Promissory Note from June 30, 2026 to August 15, 2026 and (b) increases the maximum aggregate principal amount of loan advances under the Promissory Note from $300,000 to $316,975.
Filing page
SEC filing
WLY
Wiley acquires Emerald Publishing for $452M; adds ~500 journals, expected accretive in year one
JOHN WILEY & SONS, INC.
June 2, 2026, 8:30 AM ET
m_and_a
Items 1.01, 2.01, 7.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 9.01
same event type: m_and_a
This filing
On July 29, 2025, Silo Pharma, Inc. (the “Company”) entered into an asset purchase agreement (the “Agreement”) with Many Ads Inc. (the “Seller”).
Comparable filing
entered into an Equity Purchase Agreement (the "Purchase Agreement") with CIG Emerald Midco LLC, a Delaware limited liability company (the "Seller"), and CIG Emerald Holding LLC, a Delaware limited liability company ("Emerald Holding"), pursuant to which Buyer acquired from the Seller all of the issued and outstanding equity securities of Emerald Holding (the "Transaction") in exchange for GBP £337.5 million (approximately $452 million)
Filing page
SEC filing
TVTX
Travere licenses Everest's BTK inhibitor with $112.5M upfront, up to $1.03B milestones
Travere Therapeutics, Inc.
June 2, 2026, 7:05 AM ET
m_and_a
Items 1.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 9.01
same event type: m_and_a
This filing
On July 29, 2025, Silo Pharma, Inc. (the “Company”) entered into an asset purchase agreement (the “Agreement”) with Many Ads Inc. (the “Seller”).
Comparable filing
On June 1, 2026, Travere Therapeutics, Inc. (the “Company”) entered into a license and collaboration agreement (the “Agreement”) with Everest Medicines (Singapore) Pte. Ltd. (“Everest”), pursuant to which Everest grants an exclusive license to the Company for the development and commercialization of civorebrutinib
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.